Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jun 03, 2026
Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting
07:00am, Thursday, 19'th Feb 2026
Company will debut five-year results from GALE study showing meaningful impact of early and continuous treatment with SYFOVRE ® (pegcetacoplan injection) WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIR
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Recommendation of “Hold” from Analysts
01:56am, Thursday, 19'th Feb 2026
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS - Get Free Report) have been given an average rating of "Hold" by the twenty-one analysts that are presently covering the stock, MarketBeat report
Earnings Preview: Apellis Pharmaceuticals, Inc. (APLS) Q4 Earnings Expected to Decline
11:02am, Tuesday, 17'th Feb 2026
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results
07:00am, Tuesday, 10'th Feb 2026
WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates
11:02am, Tuesday, 03'rd Feb 2026
Let us look at some drug/biotech stocks, ZTS, PCRX, APLS, ACAD and DNLI, which are poised to beat on fourth-quarter 2025 earnings.
Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains?
08:06am, Thursday, 29'th Jan 2026
Apellis Pharmaceuticals (APLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the ne
NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI)
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells $60,890.69 in Stock
05:22am, Monday, 26'th Jan 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS - Get Free Report) insider Caroline Baumal sold 2,797 shares of the stock in a transaction on Thursday, January 22nd. The stock was sold at an average price
Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells $129,052.56 in Stock
05:22am, Monday, 26'th Jan 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS - Get Free Report) insider Pascal Deschatelets sold 5,928 shares of the firm's stock in a transaction that occurred on Thursday, January 22nd. The stock was
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells $73,386.67 in Stock
05:22am, Monday, 26'th Jan 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS - Get Free Report) insider Mark Jeffrey Delong sold 3,371 shares of Apellis Pharmaceuticals stock in a transaction dated Thursday, January 22nd. The stock w
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CAO Sells $44,933.28 in Stock
05:22am, Monday, 26'th Jan 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS - Get Free Report) CAO James George Chopas sold 2,064 shares of Apellis Pharmaceuticals stock in a transaction dated Thursday, January 22nd. The stock was s
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CEO Sells $161,921.78 in Stock
05:23am, Saturday, 24'th Jan 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS - Get Free Report) CEO Cedric Francois sold 8,182 shares of the business's stock in a transaction dated Tuesday, January 20th. The stock was sold at an aver
Apellis Valuation Ignores Empaveli Potential, Says Analyst
01:14pm, Wednesday, 21'st Jan 2026
Apellis Pharmaceuticals Inc. (NASDAQ: APLS) is gaining traction in a rare kidney disease market, with early uptake of its newly approved treatment signaling a meaningful growth inflection that could r
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel Sells $128,258.20 in Stock
05:40am, Sunday, 18'th Jan 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS - Get Free Report) General Counsel David Watson sold 5,780 shares of the company's stock in a transaction on Tuesday, January 13th. The stock was sold at an
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CEO Sells $226,027.34 in Stock
05:40am, Sunday, 18'th Jan 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS - Get Free Report) CEO Cedric Francois sold 10,186 shares of the stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an a
